{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T01:58:58Z","timestamp":1777946338337,"version":"3.51.4"},"reference-count":44,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,9,20]],"date-time":"2019-09-20T00:00:00Z","timestamp":1568937600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007819","name":"Allergan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Ocular Surface"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.jtos.2019.09.006","type":"journal-article","created":{"date-parts":[[2019,9,19]],"date-time":"2019-09-19T19:14:06Z","timestamp":1568920446000},"page":"249-257","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Symptom improvement in dry eye subjects following intranasal tear neurostimulation: Results of two studies utilizing a controlled adverse environment"],"prefix":"10.1016","volume":"18","author":[{"given":"Guruprasad R.","family":"Pattar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary","family":"Jerkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David G.","family":"Evans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gail L.","family":"Torkildsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George W.","family":"Ousler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A.","family":"Hollander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Holdbrook","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Senchyna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtos.2019.09.006_bib1","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0181-5512(08)71431-1","article-title":"Severe impairment of health-related quality of life in patients suffering from ocular surface diseases","volume":"31","author":"Baudouin","year":"2008","journal-title":"J Fr Ophtalmol"},{"key":"10.1016\/j.jtos.2019.09.006_bib2","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S1542-0124(12)70082-4","article-title":"The epidemiology of dry eye disease: report of the Epidemiology Subcommittee of the International Dry Eye WorkShop","volume":"5","year":"2007","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jtos.2019.09.006_bib3","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.ajo.2006.11.060","article-title":"Impact of dry eye syndrome on vision-related quality of life","volume":"143","author":"Miljanovi\u0107","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jtos.2019.09.006_bib4","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1038\/eye.2010.67","article-title":"Impact of symptomatic dry eye on vision-related daily activities: the Singapore Malay Eye Study","volume":"24","author":"Tong","year":"2010","journal-title":"Eye"},{"key":"10.1016\/j.jtos.2019.09.006_bib5","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1167\/iovs.16-19419","article-title":"Impact of dry eye disease on work productivity, and patients' satisfaction with over-the-counter dry eye treatments","volume":"57","author":"Nichols","year":"2016","journal-title":"Invest Opthalmol Vis Sci"},{"key":"10.1016\/j.jtos.2019.09.006_bib6","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ajo.2013.02.019","article-title":"The impact of dry eye disease on visual performance while driving","volume":"156","author":"Deschamps","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jtos.2019.09.006_bib7","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1136\/bjophthalmol-2013-303838","article-title":"Dry eye disease, dry eye symptoms and depression: the Beijing Eye Study","volume":"97","author":"Labb\u00e9","year":"2013","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jtos.2019.09.006_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/02713683.2010.519850","article-title":"Anxiety and depression in patients with dry eye syndrome","volume":"36","author":"Li","year":"2010","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.jtos.2019.09.006_bib9","doi-asserted-by":"crossref","first-page":"889","DOI":"10.2147\/NDT.S81515","article-title":"High prevalence of sleep and mood disorders in dry eye patients: survey of 1,000 eye clinic visitors","author":"Ayaki","year":"2015","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.jtos.2019.09.006_bib10","series-title":"Sleep disorders and sleep deprivation: an unmet public health problem","year":"2006"},{"key":"10.1016\/j.jtos.2019.09.006_bib11","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1370\/afm.1260","article-title":"Severity of depression and magnitude of productivity loss","volume":"9","author":"Beck","year":"2011","journal-title":"Ann Fam Med"},{"key":"10.1016\/j.jtos.2019.09.006_bib12","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jtos.2017.05.006","article-title":"TFOS DEWS II management and therapy report","volume":"15","author":"Jones","year":"2017","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jtos.2019.09.006_bib13","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ajo.2003.10.036","article-title":"Antiinflammatory therapy for dry eye","volume":"137","author":"Pflugfelder","year":"2004","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jtos.2019.09.006_bib14","doi-asserted-by":"crossref","first-page":"37","DOI":"10.4137\/OED.S16067","article-title":"Safety and efficacy of cyclosporine in the treatment of chronic dry eye","volume":"6","author":"Schultz","year":"2014","journal-title":"Ophthalmol Eye Dis"},{"key":"10.1016\/j.jtos.2019.09.006_bib15","doi-asserted-by":"crossref","first-page":"951","DOI":"10.2147\/OPTH.S117188","article-title":"Lifitegrast ophthalmic solution in the treatment of signs and symptoms of dry eye disease: design, development, and place in therapy","volume":"11","author":"Godin","year":"2017","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.jtos.2019.09.006_bib16","first-page":"1","article-title":"The use of topical corticosteroids for treatment of dry eye syndrome","author":"Cutolo","year":"2017","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.jtos.2019.09.006_bib17","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jtos.2018.11.009","article-title":"Characterization of tear production in subjects with dry eye disease during intranasal tear neurostimulation: results from two pivotal clinical trials","volume":"17","author":"Sheppard","year":"2019","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jtos.2019.09.006_bib18","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s40123-017-0110-x","article-title":"Use of the controlled adverse environment (CAE) in clinical research: a review","volume":"6","author":"Ousler","year":"2017","journal-title":"Ophthalmol Ther"},{"key":"10.1016\/j.jtos.2019.09.006_bib19","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1080\/02713683.2017.1420197","article-title":"Controlled adverse environment chambers in dry eye research","volume":"43","author":"Calonge","year":"2018","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.jtos.2019.09.006_bib20","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.2147\/OPTH.S44688","article-title":"Safety and efficacy of MIM D3 ophthalmic solutions in a randomized placebo controlled phase 2 clinical trial in patients with dry eye","volume":"7","author":"Meerovitch","year":"2013","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.jtos.2019.09.006_bib21","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s12325-015-0274-5","article-title":"SkQ1 ophthalmic solution for dry eye treatment: results of a phase 2 safety and efficacy clinical study in the environment and during challenge in the controlled adverse environment model","volume":"33","author":"Petrov","year":"2016","journal-title":"Adv Ther"},{"key":"10.1016\/j.jtos.2019.09.006_bib22","first-page":"877","article-title":"Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, phase II clinical trial conducted using the controlled adverse environment (CAETM) model","volume":"9","author":"Sosne","year":"2015","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.jtos.2019.09.006_bib23","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/0003-9969(90)90080-T","article-title":"The effects of a liquid diet on initial and sustained, stimulated parotid salivary secretion and on parotid structure in the rat","volume":"35","author":"Scott","year":"1990","journal-title":"Arch Oral Biol"},{"key":"10.1016\/j.jtos.2019.09.006_bib24","first-page":"795","article-title":"A nonrandomized, open-label study to evaluate the effect of nasal stimulation on tear production in subjects with dry eye disease","volume":"10","author":"Friedman","year":"2016","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.jtos.2019.09.006_bib25","doi-asserted-by":"crossref","first-page":"6447","DOI":"10.1167\/iovs.16-20303","article-title":"Safety and efficacy clinical trials for SYL1001, a novel short interfering RNA for the treatment of dry eye disease","volume":"57","author":"Benitez-Del-Castillo","year":"2016","journal-title":"Invest Opthalmol Vis Sci"},{"key":"10.1016\/j.jtos.2019.09.006_bib26","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1089\/jop.2015.0081","article-title":"The efficacy of diquafosol ophthalmic solution in non-Sj\u00f6gren and Sj\u00f6gren syndrome dry eye patients unresponsive to artificial tear","volume":"32","author":"Jeon","year":"2016","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.jtos.2019.09.006_bib27","doi-asserted-by":"crossref","first-page":"4831","DOI":"10.1167\/iovs.16-20109","article-title":"Assessment of transepidermal water loss from the ocular area in dry eye disease","volume":"57","author":"Jeon","year":"2016","journal-title":"Invest Opthalmol Vis Sci"},{"key":"10.1016\/j.jtos.2019.09.006_bib28","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.ophtha.2013.09.015","article-title":"Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study","volume":"121","author":"Sheppard","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jtos.2019.09.006_bib29","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1016\/j.ophtha.2015.08.001","article-title":"Lifitegrast ophthalmic solution 5.0% versus placebo for treatment of dry eye disease: results of the randomized phase III OPUS-2 study","volume":"122","author":"Tauber","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jtos.2019.09.006_bib30","author":"Center for Drug Evaluation and Research"},{"key":"10.1016\/j.jtos.2019.09.006_bib31","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1017\/S0033291700009934","article-title":"Clinical applications of visual analogue scales: a critical review","volume":"18","author":"McCormack","year":"1988","journal-title":"Psychol Med"},{"key":"10.1016\/j.jtos.2019.09.006_bib32","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1136\/bjophthalmol-2014-306280","article-title":"Ocular neuropathic pain","volume":"100","author":"Rosenthal","year":"2015","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jtos.2019.09.006_bib33","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S0196-0644(96)70238-X","article-title":"Clinical significance of reported changes in pain severity","volume":"27","author":"Todd","year":"1996","journal-title":"Ann Emerg Med"},{"key":"10.1016\/j.jtos.2019.09.006_bib34","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1067\/mem.2001.118863","article-title":"Prospective validation of clinically important changes in pain severity measured on a visual analog scale","volume":"38","author":"Gallagher","year":"2001","journal-title":"Ann Emerg Med"},{"key":"10.1016\/j.jtos.2019.09.006_bib35","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1111\/j.1553-2712.1998.tb02667.x","article-title":"Does the clinically significant difference in visual analog scale pain scores vary with gender, age, or cause of pain?","volume":"5","author":"Kelly","year":"1998","journal-title":"Acad Emerg Med"},{"key":"10.1016\/j.jtos.2019.09.006_bib36","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1136\/emj.18.3.205","article-title":"The minimum clinically significant difference in visual analogue scale pain score does not differ with severity of pain","volume":"18","author":"Kelly","year":"2001","journal-title":"Emerg Med J"},{"key":"10.1016\/j.jtos.2019.09.006_bib37","first-page":"1674","article-title":"Assessment of pain in rheumatoid arthritis: minimal clinically significant difference, predictors, and the effect of anti-tumor necrosis factor therapy","volume":"34","author":"Wolfe","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jtos.2019.09.006_bib38","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ajo.2006.02.038","article-title":"Validation and repeatability of a short questionnaire for dry eye syndrome","volume":"142","author":"Gulati","year":"2006","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jtos.2019.09.006_bib39","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S1542-0124(12)70053-8","article-title":"Development and validation of a short global dry eye symptom index","volume":"5","author":"Schaumberg","year":"2007","journal-title":"Ocul Surf"},{"key":"10.1016\/j.jtos.2019.09.006_bib40","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.ophtha.2015.02.037","article-title":"Comparison of two questionnaires for dry eye symptom assessment: the Ocular Surface Disease Index and the Symptom Assessment in Dry Eye","volume":"122","author":"Amparo","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jtos.2019.09.006_bib41","article-title":"In vivo confocal microscopy demonstrates intranasal neurostimulation-induced goblet cell alterations in patients with dry eye disease (abstract)","volume":"58","author":"Dieckmann","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jtos.2019.09.006_bib42","article-title":"Intranasal neurostimulator induces morphological changes in meibomian glands in patients with dry eye disease (abstract)","volume":"58","author":"Pondelis","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jtos.2019.09.006_bib43","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ajo.2017.03.002","article-title":"Randomized controlled crossover trial comparing the impact of sham or intranasal tear neurostimulation on conjunctival goblet cell degranulation","volume":"177","author":"Gumus","year":"2017","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jtos.2019.09.006_bib44","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1001\/archophthalmol.2009.356","article-title":"Minimal clinically important difference for the ocular surface disease index","volume":"128","author":"Miller","year":"2010","journal-title":"Arch Ophthalmol"}],"container-title":["The Ocular Surface"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S154201241930196X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S154201241930196X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T04:38:35Z","timestamp":1761539915000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S154201241930196X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S154201241930196X"],"URL":"https:\/\/doi.org\/10.1016\/j.jtos.2019.09.006","relation":{},"ISSN":["1542-0124"],"issn-type":[{"value":"1542-0124","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Symptom improvement in dry eye subjects following intranasal tear neurostimulation: Results of two studies utilizing a controlled adverse environment","name":"articletitle","label":"Article Title"},{"value":"The Ocular Surface","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtos.2019.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}